SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (781)7/12/1999 7:52:00 PM
From: scaram(o)ucheRespond to of 4974
 
yeahrightsure....... geeeze, I have grown to resent this company for what they are doing to biotech.......

Monday July 12, 6:51 pm Eastern Time

Company Press Release

SOURCE: Advanced Tissue Sciences, Inc.

Advanced Tissue Sciences Files Registration
Statement for Offering

LA JOLLA, Calif., July 12 /PRNewswire/ -- Advanced Tissue Sciences, Inc. (Nasdaq: ATIS - news) today reported that it has
filed a registration statement with the Securities and Exchange Commission (SEC) for an offering of 5,000,000 shares of Common
Stock. The Common Stock is being offered directly by the Company.
(snip)

iqc.com



To: scaram(o)uche who wrote (781)7/13/1999 12:06:00 PM
From: BluegreenRead Replies (1) | Respond to of 4974
 
I disagree with your comments on having to use shotgun medicine IF Neuprex is approved. In most cases of gram neg. infections conventional antibiotics with rBPI21 will suffice if given early enough. Of course, just my humble opinion.